Fábio Vieira Teixeira

Fábio Vieira Teixeira

Auto-generated profile, based on publicly available information

Fábio Vieira Teixeira

Clínica GastroSaúde, Brasil

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
Britta SiegmundBritta Siegmund
Britta Siegmund
RFRoger M. Feakins
Roger M. Feakins
GBGiorgos Bamias
Giorgos Bamias
JLJuliano Coelho Ludvig
Juliano Coelho Ludvig
FTFabio Vieira Teixeira
Fabio Vieira Teixeira
MSMichael Scharl
Michael Scharl
The fifth scientific workshop of the European Crohn’s and Colitis Organization (ECCO) focused on the relevance of fistulas to the disease course of patients with Crohn’s disease (CD). The objectives were to reach a better understanding of the pathophysiological mechanisms underlying the formation of CD fistulas; to identify future topics in fistula research that could provide insights into pathogenesis; to develop novel therapeutic approaches; and to review current therapeutic strategies (with clarification of existing approaches to prevention, diagnosis and treatment). The results of the workshop are presented in two separate manuscripts. This manuscript describes current state-of-the-art knowledge about fistula pathogenesis, including the roles of epithelial-to-mesenchymal transition and cytokine matrix remodelling enzymes, and highlights the common association between fistulas and stenosis in CD. The review also considers the possible roles that genetic predisposition and intestinal microbiota play in fistula development. Finally, it proposes future directions and needs for fistula research that might substantially increase our understanding of this complex condition and help unravel novel therapeutic strategies and specific targets for treatment. Overall, it aims to highlight unanswered questions in fistula research and to provide a framework for future research work.

1 August 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
Rafael DenadaiRafael Denadai
Rafael Denadai
FTFábio Vieira Teixeira
Fábio Vieira Teixeira
FSFlavio Steinwurz
Flavio Steinwurz
RRRicardo Romiti
Ricardo Romiti
RSRogerio Saad-Hossne
Rogerio Saad-Hossne
Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. Published studies were identified by a search of Medline, Embase, Cochrane, SciELO, and LILACS databases. A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222 patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient age was 26.50 years, and 70.72% of patients had no history of psoriasis. Patients developed psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete remission of cutaneous lesions was observed in 63.96% of the cases. We found that psoriatic lesions occurred predominantly in adult patients with Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients can be managed conservatively without discontinuing anti-TNF-α therapy.

1 December 2016 in United European Gastroenterology Journal
Verified
Journal Article
Open access
TYTakayuki Yamamoto
Takayuki Yamamoto
ASAntonino Spinelli
Antonino Spinelli
YSYasuo Suzuki
Yasuo Suzuki
RSRogerio Saad-Hossne
Rogerio Saad-Hossne
FTFabio Vieira Teixeira
Fabio Vieira Teixeira
PKPaulo Kotze
Paulo Kotze
Background: In the era of biologic agents, risk factors for complications following resection for Crohn’s disease have not been fully identified. In particular, the association of preoperative use of immunosuppressive and biologic agents with the incidence of complications after resection remains to be elucidated.Aim: This retrospective multicentre study aimed to identify risk factors for complications after ileocolonic resection for Crohn’s disease, with a major focus on the impact of preoperative immunosuppressive and biologic therapy.Methods: A total of 231 consecutive patients who underwent ileocolonic resections for active Crohn’s disease in seven inflammatory bowel disease referral centres from three countries (Japan, Brazil and Italy) were included. The following variables were investigated as potential risk factors: age at surgery, gender, behaviour of Crohn’s disease (perforating vs. non‐perforating disease), smoking, preoperative use (within eight weeks before surgery) of steroids, immunosuppressants and biologic agents, previous resection, blood transfusion, surgical procedure (open vs. laparoscopic approach), and type of anastomosis (side‐to‐side vs. end‐to‐end). Postoperative complications occurring within 30 days after surgery were recorded.Results: The rates of overall complications, intra‐abdominal sepsis, and anastomotic leak were 24%, 12% and 8%, respectively. Neither immunosuppressive nor biologic therapy prior to surgery was significantly associated with the incidence of overall complications, intra‐abdominal sepsis or anastomotic leak. In multivariate analysis, blood transfusion, perforating disease and previous resection were significant risk factors for overall complications (odds ratio [OR] 3.02, 95% confidence interval [CI] 1.21–7.52; P = 0.02), intra‐abdominal sepsis (OR 2.67, 95% CI 1.04–6.86; P = 0.04) and anastomotic leak (OR 2.87, 95% CI 1.01–8.18; P = 0.048), respectively.Conclusions: Blood transfusion, perforating disease and previous resection were significant risk factors for overall complications, intra‐abdominal sepsis and anastomotic leak after ileocolonic resection for Crohn’s disease, respectively. Preoperative immunosuppressive or biologic therapy did not increase the risk of postoperative complications.

10 December 2016 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
IBI. F. de Barcelos
I. F. de Barcelos
PKPaulo Kotze
Paulo Kotze
ASAntonino Spinelli
Antonino Spinelli
YSY. Suzuki
Y. Suzuki
FTF. V. Teixeira
F. V. Teixeira
TYTakayuki Yamamoto
Takayuki Yamamoto

28 March 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
PKPaulo Kotze
Paulo Kotze
TYTakayuki Yamamoto
Takayuki Yamamoto
SDSilvio Danese
Silvio Danese
YSYasuo Suzuki
Yasuo Suzuki
FTFabio Vieira Teixeira
Fabio Vieira Teixeira
ASAntonino Spinelli
Antonino Spinelli
Both adalimumab [ADA] and infliximab [IFX] seem to be effective in the prevention of early postoperative endoscopic recurrence [EPER] after ileocaecal resection in Crohn’s disease [CD] patients. There is lack of data with direct comparison between the two agents in the postoperative scenario. The aim of this study was to compare the rates of EPER in patients treated with ADA and IFX after ileocaecal resection for CD. This was a multicentre retrospective analysis of EPER rates in CD patients after ileocaecal resections, from seven referral centres in three countries. Endoscopic recurrence was defined as Rutgeerts’ score ≥ i2. The patients were allocated according to treatment to two groups: ADA or IFX. The EPER rates were compared between the two treatment groups. Among the 168 patients included in the database, 96 received anti-tumour necrosis factor [TNF] agents after resection [37 in the ADA and 59 in the IFX groups] and were included in this comparative study. The groups were comparable in all baseline characteristics, mainly age, gender, previous resections, perianal CD, and mono or combination therapy. EPER was identified in 9/37 [24.32%] in the ADA group vs 16/59 [27.12%] in the IFX group [p = 0.815]. In this retrospective direct comparison between ADA and IFX therapy after ileocaecal resection, there was no significant difference between the two anti-TNF agents in terms of EPER rates. However, prospective randomised studies are needed to confirm these data and better define the role of each agent in the prevention of EPER.

1 May 2005 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
FTFabio V Teixeira
Fabio V Teixeira
TNTânia M S Novaretti
Tânia M S Novaretti
BPBenedito Pilon
Benedito Pilon
PPPriscila G Pereira
Priscila G Pereira
MBMaria Fernanda C L Breda
Maria Fernanda C L Breda